236 related articles for article (PubMed ID: 26207830)
1. Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.
Kang H; Jeong JY; Song JY; Kim TH; Kim G; Huh JH; Kwon AY; Jung SG; An HJ
Mol Carcinog; 2016 Jul; 55(7):1196-209. PubMed ID: 26207830
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Effect of Notch-3-Specific Inhibition and Paclitaxel in Non-Small Cell Lung Cancer (NSCLC) Cells Via Activation of The Intrinsic Apoptosis Pathway.
He F; Du T; Jiang Q; Zhang Y
Med Sci Monit; 2017 Aug; 23():3760-3769. PubMed ID: 28769027
[TBL] [Abstract][Full Text] [Related]
4. Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer.
Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama S; Otsuki Y; Miyazaki K
Am J Clin Pathol; 2012 Oct; 138(4):535-44. PubMed ID: 23010708
[TBL] [Abstract][Full Text] [Related]
5. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel.
Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y
Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
7. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.
Risnayanti C; Jang YS; Lee J; Ahn HJ
Sci Rep; 2018 May; 8(1):7498. PubMed ID: 29760419
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.
Wang M; Ma X; Wang J; Wang L; Wang Y
Int J Oncol; 2014 Apr; 44(4):1401-9. PubMed ID: 24535252
[TBL] [Abstract][Full Text] [Related]
9. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
[TBL] [Abstract][Full Text] [Related]
10. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
[TBL] [Abstract][Full Text] [Related]
12. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
[TBL] [Abstract][Full Text] [Related]
13. Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer.
Lee HW; Kim SJ; Choi IJ; Song J; Chun KH
Clin Exp Metastasis; 2015 Aug; 32(6):593-603. PubMed ID: 26134677
[TBL] [Abstract][Full Text] [Related]
14. Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.
Wang H; Fan L; Xia X; Rao Y; Ma Q; Yang J; Lu Y; Wang C; Ma D; Huang X
Int J Gynecol Cancer; 2012 Jun; 22(5):755-61. PubMed ID: 22635028
[TBL] [Abstract][Full Text] [Related]
15. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.
McAuliffe SM; Morgan SL; Wyant GA; Tran LT; Muto KW; Chen YS; Chin KT; Partridge JC; Poole BB; Cheng KH; Daggett J; Cullen K; Kantoff E; Hasselbatt K; Berkowitz J; Muto MG; Berkowitz RS; Aster JC; Matulonis UA; Dinulescu DM
Proc Natl Acad Sci U S A; 2012 Oct; 109(43):E2939-48. PubMed ID: 23019585
[TBL] [Abstract][Full Text] [Related]
16. Notch1 downregulation combined with interleukin-24 inhibits invasion and migration of hepatocellular carcinoma cells.
Han B; Liu SH; Guo WD; Zhang B; Wang JP; Cao YK; Liu J
World J Gastroenterol; 2015 Sep; 21(33):9727-35. PubMed ID: 26361419
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of piperine and paclitaxel on cell fate via cyt-c, Bax/Bcl-2-caspase-3 pathway in ovarian adenocarcinomas SKOV-3 cells.
Pal MK; Jaiswar SP; Srivastav AK; Goyal S; Dwivedi A; Verma A; Singh J; Pathak AK; Sankhwar PL; Ray RS
Eur J Pharmacol; 2016 Nov; 791():751-762. PubMed ID: 27756602
[TBL] [Abstract][Full Text] [Related]
18. Regulation of pancreatic stellate cell activation by Notch3.
Song H; Zhang Y
BMC Cancer; 2018 Jan; 18(1):36. PubMed ID: 29304760
[TBL] [Abstract][Full Text] [Related]
19. hMSH2 expression is associated with paclitaxel resistance in ovarian carcinoma, and inhibition of hMSH2 expression in vitro restores paclitaxel sensitivity.
Zhang J; Yin D; Li H
Oncol Rep; 2014 Nov; 32(5):2199-206. PubMed ID: 25175513
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
Xu Y; Zhang J; Wu J; Zhong S; Li H
Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]